Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events

Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events

An Interactive, Virtual Program at the PCR eCourse 2020


Friday, June 26th, 2020
17:15 – 18:00 GMT+2
16:15 – 17:00 GMT+1
11:15 am – 12:00 pm ET


Interactive, Virtual Program
Now Open

Program Overview

Heart disease continues to be the leading cause of mortality in Europe. Despite advances in prevention and therapy, each year cardiovascular disease (CVD) causes over 1.8 million deaths in the European Union (EU).  CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU, is the main cause of death in men in all but 12 countries of Europe, and is the main cause of death in women in all but two countries. Acute coronary syndromes (ACS) comprise a substantial portion of these grim statistics, and better care for ACS patients could improve clinical and economic outcomes in the EU.  While evidence-based society guidelines recommend aggressive dual antiplatelet therapy (DAPT) for such patients, contemporary practice data on both sides of the Atlantic indicate that DAPT is underutilized both early after an index MI and for evidence-grounded durations of therapy.  In addition, in 2019 new data were published that demand re-evaluation of oral antiplatelet drug choice and of the role of long-term aspirin therapy in secondary prevention of ACS.  Education of all stakeholders in ACS/MI care—particularly interventional cardiologists—about the guidelines and their basis, and about improving practice to reflect recommendations for care, especially around DAPT, can improve outcomes in ACS.



  • Overview of Controversies in Secondary Prevention of ACS
  • The Foundational Role of Antiplatelet Therapy in Secondary Prevention of ACS
  • Risk Stratification for Secondary Ischemia vs Bleeding Complications with Antiplatelet Therapy
  • Is the Acetylsalicylic Acid Component of DAPT Required for the Duration?
  • What is the Clinical Impact of Antiplatelet Agent Choice in Secondary Prevention? An Analysis of ISAR-REACT 5
  • Interactive Panel Discussion and Virtual Question and Answers


Educational Objectives

  1. Describe the latest evidence-based guideline recommendations for secondary prevention of ACS/MI
  2. Review the foundational role of antiplatelet therapy in secondary prevention of ACS/MI and manage their patients accordingly, with appropriate attention to risk benefit balance
  3. Discuss the pertinent findings of recent trials of anti-platelet therapy in ACS, placing them in the context of prior data, established practice, and current guidelines



Charles V. Pollack Jr., MA, MD
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Tobias Geisler, MD, MHBA, FESC
Consultant/Vice Head of Department
Department of Cardiology and Angiology
Tübingen, Germany

Philippe Gabriel Steg, MD
Professor of Cardiology
Université Paris-Diderot
Paris, France

Robert Storey BSc, BM, DM
Professor of Cardiology
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Sheffield, United Kingdom

Uwe Zeymer, MD
Senior Cardiologist
Klinikum Ludwigshafen
Ludwigshafen, Germany


Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.




The event “Controversies in Antiplatelet Therapy for the Secondary Prevention of Cardiovascular Events” is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1.0  hours of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).”


Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™. This program will be accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 1.0 European CME credit (ECMEC®). Clinicians should claim only the credit commensurate with the extent of their participation in the activity.


CE Inquiries/Special Needs

For all CME/CE inquiries or special needs, please contact [email protected] or 610-687-3300.


Financial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals



To tune in to the session today, you must first register for the complimentary general PCR eCourse using this link:

Once registered for the 2020 eCourse, you can access our session at 17:15 GMT+2, 16:15 GMT+1, 11:15 am ET by clicking the below link directly:!/Auditorium/n447004/c225530. A few minutes prior to the event, a ‘Play’ button will appear where the ‘Scheduled’ button is currently located. The event can also be found under the Case Based Learning Channel.

Following the program, please visit to take the evaluation and claim CME credit. For any questions/issues, please email [email protected].


Provided by AcademicCME